Dogwood Therapeutics said it has started a 12-week open-label extension study of Halneuron after a positive interim assessment in its ongoing Phase 2b chemotherapy-induced neuropathic pain trial. The company said the follow-on study will add safety and efficacy data for its planned FDA submission package and future Phase 3 program.
Dogwood Therapeutics said on May 18 that it has started a 12-week open-label extension study of Halneuron in chemotherapy-induced neuropathic pain, following a positive interim assessment in the ongoing Phase 2b trial.
The company said the follow-on study is designed to collect additional safety and efficacy data from patients who complete the original 4-week double-blind Phase 2b study. Dogwood said several patients had already enrolled.
The extension is intended to support the company’s planned FDA submission package and its projected Phase 3 program. Dogwood previously said Phase 2b data were expected in fall 2026.
Reuters-syndicated market coverage carried the same announcement the same day.
What happens next
Dogwood has not publicly disclosed how many patients will join the extension or when it expects results from the follow-on study. Those data will be watched for clues on the next step in Halneuron’s development path.
Revision note
Initial automated publication.